🔥 BioBoom Season: Why Fall & Winter Spark the Biggest Biotech Breakouts

The fall and winter months are historically the most explosive for biotech catalysts.

Here’s why the timing matters…

1. FDA Deadlines Cluster in Q4

Biotech companies that file New Drug Applications (NDAs) or Biologics License Applications (BLAs) earlier in the year often land their PDUFA decision dates in October–December. The FDA also tends to clear its backlog before the holidays, resulting in a surge of approvals and rejections late in the year.

2. Major Medical Conferences Drive Headlines

ESMO (Oncology) – September/October
AHA (Cardiology) – November
ASH (Hematology) – December
Obesity & Metabolic – Fall (various)

Companies plan Phase 2/3 readouts to coincide with these events, ensuring maximum visibility. This creates waves of clinical catalysts stacked in just a few weeks.

3. Market Dynamics Add Fuel

After a slow summer, traders come back energized in September. Tax-loss harvesting in late fall pushes weak biotechs down, making the winners stand out even more. Meanwhile, big pharma frequently announces M&A deals in Q4, adding another layer of momentum across the sector.

💡 Quick Takeaway

Fall and winter are the prime time for biotech breakouts. FDA deadlines, stacked trial readouts, and renewed market focus all collide in a few short months. ScanScor tracks these catalysts so you can be positioned before the crowd.

Stay Ahead of the Surge